Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 4, 2008, Pages 1412-1417

  Ferone, Diego ^a,c   De Herder, Wouter W ^a   Pivonello, Rosario ^b   Kros, Johan M ^a   Van Koetsveld, Peter M ^a   De Jong, Ton ^a   Minuto, Francesco ^c   Colao, Annamaria ^b   Lamberts, Steven W J ^a   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PROLACTIN; QUINAGOLIDE; RECEPTOR SUBTYPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR SUBTYPE 2A; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; AGED; ARTICLE; CELL TYPE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DOPAMINE RELEASE; ELECTRON MICROSCOPY; FEMALE; GROWTH HORMONE SECRETING ADENOMA; GROWTH HORMONE SECRETING CELL; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REGULATORY MECHANISM; SOMATOSTATIN CELL;

EID: 42149145552     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-1358     Document Type: Article

References (20)

1. Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E, A.L.I.C.E. Study Group 2006 First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest 29:1017-1020
2. Moller LN, Stidsen CE, Hartmann B, Holst JJ 2003 Somatostatin receptors. Biochim Biophys Acta 1616:1-84
3. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P 2001 Bim-23244, a somatostatin receptor subtype 2-and -5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 86:140-145
4. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts SW 2004 The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89:1577-1585
5. Taboada GF, Luque RM, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR 2007 Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65-74
6. Ivan G, Szigeti-Csucs N, Olah M, Nagy GM, Goth MI 2005 Treatment of pituitary tumors: dopamine agonists. Endocrine 28:101-110
7. Burt MG, Ho KK 2006 Newer options in the management of acromegaly. Intern Med J 36:437-444
8. Asa S, Kovacs K, Horvath E, Singer W, Smyth HS 1992 Hormone secretion in vitro by plurihormonal pituitary adenomas of the acidophilic cell line. J Clin Endocrinol Metab 75:68-75
9. Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A 2001 In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clin Endocrinol (Oxf) 54:469-477
10. Hofland LJ, Liu Q, van Koetsveld PM, Zujderwijk J, van der Ham F, de Krjger RR, Schonbrunn A, Lamberts SWJ 1999 Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 84:775-780
11. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW 2004 Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452-2462
12. de Herder WW, Taal HR, Uitterlinden P, Feelders RA, Janssen JA, van der Lely AJ 2005 Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol 153:67-71
13. Oosterom R, Blaauw G, Singh R, Verleun T, Lamberts SW 1984 Isolation of large numbers of dispersed human pituitary adenoma cells obtained by aspiration. J Endocrinol Invest 7:307-311
14. Ferone D, van Hagen MP, Kwekkeboom DJ, van Koetsveld PM, Mooy DM, Lichtenauer-Kaligis E, Schonbrunn A, Colao A, Lamberts SW, Hofland LJ 2000 Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 85:1719-1726
15. Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA 2005 The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol (Oxf) 62:282-288
16. Cozzi R, Attanasio R, Lodrini S, Lasio G 2004 Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 61:209-215
17. Selvarajah D, Webster J, Ross R, Newell-Price J 2005 Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 152:569-574
18. Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD 2006 Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 29:826-830
19. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D 2007 Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92:1592-1599
20. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC 2000 Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:154-157